Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses.

arterial hypertension non-interventional study overactive bladder syndrome pathophysiology solifenacin treatment

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2022
Historique:
received: 26 10 2022
accepted: 01 12 2022
entrez: 30 12 2022
pubmed: 31 12 2022
medline: 31 12 2022
Statut: epublish

Résumé

While animal studies have suggested an association between the presence of hypertension and the presence and/or severity of overactive bladder syndrome (OAB) symptoms, little clinical data is available. We have conducted a pre-specified secondary analysis of a non-interventional study involving 4450 OAB patients being treated with solifenacin to explore the existence of an association between OAB and hypertension using three parallel and overlapping definitions of hypertension to enhance robustness of analysis. Regardless of definition, patients with hypertension were older and had greater OAB symptom severity in univariate analyses. In multiple regression models including age as explanatory covariate, most relationships held up but effect sizes of concomitant hypertension on OAB severity were small (odds ratios <1.35 in all cases) and were deemed to be unlikely of clinical relevance. % Changes in symptom severity were somewhat smaller in univariate analysis, but effect sizes were small. We conclude that OAB and arterial hypertension are associated but effect sizes are too small to justify adaptation of clinical practice for OAB patients with concomitant hypertension.

Identifiants

pubmed: 36582525
doi: 10.3389/fphar.2022.1081074
pii: 1081074
pmc: PMC9792767
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1081074

Informations de copyright

Copyright © 2022 Michel, Heemann and de la Rosette.

Déclaration de conflit d'intérêts

MM has been a consultant and/or speaker for Apogepha, Astellas, Willmar Schwabe and GSK. UH and JdlR declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Pharmacol Rev. 1999 Dec;51(4):651-90
pubmed: 10581327
Expert Opin Drug Saf. 2016 May;15(5):647-57
pubmed: 26954275
Obstet Gynecol. 2015 Jun;125(6):1423-1432
pubmed: 26000514
Int J Clin Pract. 2013 Nov;67(11):1138-43
pubmed: 24165427
J Urol. 1999 Apr;161(4):1372-7
pubmed: 10081910
J Urol. 2000 Jun;163(6):1725-9
pubmed: 10799169
J Urol. 2015 Jan;193(1):345-51
pubmed: 25171907
Am J Physiol. 1998 Oct;275(4):R1366-73
pubmed: 9756570
Neurourol Urodyn. 2020 Feb;39(2):754-761
pubmed: 31945207
Eur Urol. 2015 Jul;68(1):97-112
pubmed: 25572826
Eur Urol. 2008 Sep;54(3):543-62
pubmed: 18599186
Eur Urol. 2006 Sep;50(3):581-6
pubmed: 16519993
Handb Exp Pharmacol. 2020;257:163-175
pubmed: 31598837
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
Exp Physiol. 1999 Jan;84(1):137-47
pubmed: 10081714
Neurourol Urodyn. 2007;26(2):190-5
pubmed: 17096320
Naunyn Schmiedebergs Arch Pharmacol. 2015 Jul;388(7):687-94
pubmed: 26026700
Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F738-F743
pubmed: 26792064
Urology. 2006 Dec;68(6):1198-205
pubmed: 17169643
World J Urol. 2011 Apr;29(2):179-84
pubmed: 20963421
Mol Pharmacol. 2020 Jan;97(1):49-60
pubmed: 31882404
Int J Obes (Lond). 2005 Mar;29(3):310-6
pubmed: 15672112
PLoS One. 2014 Sep 12;9(9):e107593
pubmed: 25216271
Br J Pharmacol. 2008 Apr;153(8):1659-68
pubmed: 18297104
Neurourol Urodyn. 2011 Sep;30(7):1392-402
pubmed: 21661033
Neurourol Urodyn. 2011 Apr;30(4):510-4
pubmed: 21351125
Nature. 2021 Apr;592(7855):524-533
pubmed: 33883728
Prostate Cancer Prostatic Dis. 2014 Sep;17(3):265-72
pubmed: 25000909
Brain Res. 1998 Apr 20;790(1-2):151-9
pubmed: 9593870
Urol Int. 2016;97(3):330-335
pubmed: 27509202
Neurourol Urodyn. 2002;21(2):167-78
pubmed: 11857671
Neurourol Urodyn. 2012 Jan;31(1):195-200
pubmed: 21905085
J Urol. 2008 Jun;179(6):2470-6
pubmed: 18433789
J Urol. 2004 Oct;172(4 Pt 1):1390-3
pubmed: 15371852
Am J Epidemiol. 2003 May 15;157(10):906-14
pubmed: 12746243
JAMA. 2000 Apr 19;283(15):1967-75
pubmed: 10789664
Drug Saf. 2008;31(6):505-14
pubmed: 18484784
BJU Int. 2007 Nov;100(5):1007-14
pubmed: 17922785

Auteurs

Martin C Michel (MC)

Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany.

Uwe Heemann (U)

Department of Medicine, University Medical Center, Munich, Germany.

Jean J M C H de la Rosette (JJMCH)

Department of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul, Turkey.

Classifications MeSH